mRNA Vaccines and Monoclonal Antibodies for Therapy
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Therapeutic Vaccines and Antibody Therapeutics".
Deadline for manuscript submissions: 28 February 2025 | Viewed by 721
Special Issue Editors
Interests: autoimmune; vaccination; public health, health promotion
Interests: vaccines; therapies; communicable diseases; hesitancy; acceptance
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
mRNA vaccines and monoclonal antibodies are emerging, promising treatments. mRNA vaccines contain messenger RNA (mRNA) which carries instructions to produce a specific protein. Once inside our body's cells, the mRNA acts as a blueprint to create a viral protein. Then, this protein induces specific antibodies. These antibodies persist for between 4 and 6 months, but immune cells remember how to defend against future infections. mRNA vaccines and monoclonal antibodies show promise in personalized medicine, thereby offering hope for improved outcomes and reduced side effects compared to those of traditional treatments. This Special Issue aims to provide insights into the safe, effective use of mRNA vaccines and of monoclonal antibodies. Novel articles, reviews, and preclinical studies that use human-relevant models or studies on humans are encouraged.
Dr. Giovanni Genovese
Dr. Cristina Genovese
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccinations
- vaccines
- immunotherapy
- active immunization
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
